Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeterna Zentaris (NQ: AEZS )

0.6364 USD +0.0041 (+0.65%)
Streaming Delayed Price Updated: 3:44 PM EDT, Sep 28, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 917,122
Open 0.6301
Bid (Size) 0.6302 (1)
Ask (Size) 0.6365 (3)
Prev. Close 0.6323
Today's Range 0.6126 - 0.6400
52wk Range 0.2900 - 3.620
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From GlobeNewswire News Releases
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
From GlobeNewswire News Releases

Performance

YTD
+23.60%
+23.60%
1 Month
-8.56%
-8.56%
3 Month
-28.28%
-28.28%
6 Month
-42.67%
-42.67%
1 Year
+85.49%
+85.49%

More News

Read More
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
From GlobeNewswire News Releases
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
From GlobeNewswire News Releases
Top Biotech Penny Stocks to Buy This Week? 9 To Watch
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
From GlobeNewswire News Releases
Best Penny Stocks To Buy Now? 7 To Watch This Week
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS,
From GlobeNewswire News Releases
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
From GlobeNewswire News Releases
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
From GlobeNewswire News Releases
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.